Jack pot! What can we learn about registries with respect to treatment cycling in rheumatoid arthritis?

Pope, Janet; Fleischmann, Roy

doi:10.1136/ard-2022-223071

Ann Rheum Dis

2023

DOI: 10.1136/ard-2022-223071

|View full text |Cite

Jack pot! What can we learn about registries with respect to treatment cycling in rheumatoid arthritis?

Janet Pope

Roy Fleischmann

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Baricitinib: key results of long-term use in rheumatoid arthritis

Chichasova,

Lila

2024

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

This review presents the latest data on the long-term use of the selective Janus kinase inhibitor (JAKi) baricitinib (BARI) in patients with rheumatoid arthritis (RA) in real-world clinical practice. The results of long-term use (up to 9.5 years) of BARI in RA suggest that its efficacy is comparable or even superior to that of biologic disease-modifying antirheumatic drugs (bDMARDs) and tofacitinib, while the drug is more effective in patients who have not previously received bDMARDs or JAKi. It has been shown that the BARI dose can be reduced to 2 mg/day once the treatment goal has been reached in most patients without a decrease in efficacy, and that exacerbations that have occurred after reduction of the dosage (or treatment interruption) are relieved when returning to the full dose of the drug. According to data from registries from many countries and open observational studies, BARI is well tolerated during long-term use, even in elderly patients with ≥1 risk factor for cardiovascular disease. A high survival rate with BARI therapy has also been observed, which according to some registries exceeds that of tumor necrosis factor α inhibitors. Against the background of BARI therapy, a rapid (within 1 to 3 months) statistically significant reduction in pain has been demonstrated, regardless of the degree of suppression of disease activity, which correlates with an improvement in the functional status and general condition of patients. The possibility of suppressing the progression of structural damage in patients with RA was also demonstrated, allowing the choice of individualized tactics for the management of such patients.

show abstract

Baricitinib: key results of long-term use in rheumatoid arthritis

Chichasova,

Lila

2024

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Jack pot! What can we learn about registries with respect to treatment cycling in rheumatoid arthritis?

Cited by 1 publication

References 20 publications

Baricitinib: key results of long-term use in rheumatoid arthritis

Baricitinib: key results of long-term use in rheumatoid arthritis

Contact Info

Product

Resources

About